Out-of-network billing continues to become more common for patients with private insurance even when seeking treatment at in-network hospitals, which creates a financial strain for many patients, according to study results published by JAMA Internal Medicine.
Patients with complex needs may need more complex solutions to manage their health issues. Innovations in technology and integration of data have made it possible to improve patient interactions with the pharmacy to better manage their diseases. The American Journal of Managed Care® recently spoke with Christine Sawicki, senior director, specialty product development and innovation, CVS Health, about the impact new technology can have on patient experience, health outcomes, and drug spending.
The cost of radiation oncology services has typically been a small part of the Medicare and Medicaid budget, but with more patients having complex radiation treatments, it is becoming more important to have alternative payment models in the space, said Shalom Kalnicki, MD, FASTRO, FACRO, professor and chairman, radiation oncology, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine.
Employers are looking for ways to advocate for their employees and invest in places that will reduce downstream costs, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
New and effective antibiotics are rarely prescribed in carbapenem-resistant Enterobacteriaceae (CRE) infections, which are a family of the most drug-resistant bacteria.
A case report of a 35-year-old woman with chronic migraine who had a 2-year history of severe pain that did not improve with medical therapy showed that peripheral nerve field stimulation could safely treat chronic migraine.
As health costs continue to increase, health spending by families with large employer health plans has increased 2 times faster than workers’ wages over the last 10 years.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Fatal adverse events (AEs) associated with alemtuzumab for multiple sclerosis (MS) may occur more frequently than previously understood based on past published literature, researchers found.
This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.
Regeneron released positive phase 3 results for evinacumab, a drug for a rare form of deadly high cholesterol, and said it expects to seek FDA approval in 2020.
Traditionally, migraine is thought of as an issue of lost productivity, but there is evidence that there are direct costs on the medical claims side, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Business leaders discuss challenges of providing healthcare to employees and what has changed in the last few years.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Health plans on the Affordable Care Act (ACA) exchanges will be required to display quality ratings starting with the 2020 plan year, according to an announcement from CMS, which is expanding the 5-star rating system it uses on Medicare plans to the health insurance exchanges.
Value-based programs such as accountable care organizations appear to encourage the adoption and spread of care coordination activities by hospitals.
The FDA ordered 4 companies to stop selling 44 of their flavored e-liquid and hookah tobacco products that lack the required approval for sale; CMS has yet to implement a 2014 law preventing unnecessary, expensive screening tests (magnetic resonance imaging, computed tomagraphy scans and other tests) that could harm patients and waste resources; Amarin, which is seeking FDA approval for an expansion of Vascepa labeling to include data that showed a 25% reduction in the risk of heart attacks and strokes, said the FDA has scheduled an advisory committee meeting for November 14.
Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray.
Several physician and payer characteristics are associated with physician satisfaction with health plans. There is opportunity to improve physician satisfaction with payers, specifically in pharmacy.
The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
The upfront prices of potentially curative therapies are terrifying to commercial payers and government payers alike. A panel on the last day of ISPOR 2019 discussed these issues in a session called, “Is Affordability Driving a Need to Revolutionize Drug Pricing?”
Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not appear to affect patient-reported chronic obstructive pulmonary disease (COPD) symptom scores.
A report from the Health Care Cost Institute examined 4 years' worth of data covering 1.8 billion claims in 112 markets.
We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.
